Deep Chahodiya
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Role not yet determined Is this you? Add your title
Also affiliated: University of Wisconsin–Madison (2026); New York Hospital Queens (2026); Government Medical College (2025–2026)
Research Areas
Biography and Research Information
OverviewAI-generated summary
Deep Chahodiya's research focuses on meta-analyses and systematic reviews of clinical studies, investigating treatment efficacy and patient outcomes across various medical conditions. Recent work has examined the impact of sodium glucose cotransporter-2 inhibitors on ventricular arrhythmia in patients with implantable cardioverter-defibrillators, the lipid-lowering efficacy of obicetrapib, and trends in procedure-related mortality among older adults with digestive system malignancies. Other investigations include demographic and regional trends in colorectal cancer and cerebrovascular disease-related mortality, the effectiveness of adding panitumumab to chemotherapy regimens for metastatic colorectal cancer, and the efficacy of vonoprazan-based dual therapy for H. pylori eradication. Chahodiya has also studied the therapeutic efficacy of dapagliflozin on liver fibrosis, steatosis, and metabolic parameters in patients with metabolic dysfunction-associated steatotic liver disease. Collaborations include 19 shared publications with L. Thaker at the University of Arkansas for Medical Sciences.
Metrics
- h-index: 1
- Publications: 25
- Citations: 2
Selected Publications
-
E-93 | Population-level Impact of Advancing Valvular Interventions on Mortality from Atrial Fibrillation and Flutter Among Adults with Nonrheumatic Valvular Heart Disease in the United States: A CDC-WONDER Analysis from 1999-2023 (2026)
Collaboration Network
Top Collaborators
- E-93 | Population-level Impact of Advancing Valvular Interventions on Mortality from Atrial Fibrillation and Flutter Among Adults with Nonrheumatic Valvular Heart Disease in the United States: A CDC-WONDER Analysis from 1999-2023
- E-93 | Population-level Impact of Advancing Valvular Interventions on Mortality from Atrial Fibrillation and Flutter Among Adults with Nonrheumatic Valvular Heart Disease in the United States: A CDC-WONDER Analysis from 1999-2023
- E-93 | Population-level Impact of Advancing Valvular Interventions on Mortality from Atrial Fibrillation and Flutter Among Adults with Nonrheumatic Valvular Heart Disease in the United States: A CDC-WONDER Analysis from 1999-2023
- E-93 | Population-level Impact of Advancing Valvular Interventions on Mortality from Atrial Fibrillation and Flutter Among Adults with Nonrheumatic Valvular Heart Disease in the United States: A CDC-WONDER Analysis from 1999-2023
- E-93 | Population-level Impact of Advancing Valvular Interventions on Mortality from Atrial Fibrillation and Flutter Among Adults with Nonrheumatic Valvular Heart Disease in the United States: A CDC-WONDER Analysis from 1999-2023
Similar Researchers
Based on overlapping research topics